US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Alto Neuroscience Inc

20.50

-0.3200-1.54%

Post-market: 20.500.00000.00%18:16 EDT

Volume:201.86K

Turnover:4.12M

Market Cap:636.86M

PE:-9.35

High:21.42

Open:20.70

Low:19.85

Close:20.82

52wk High:25.17

52wk Low:1.60

Shares:31.07M

Float Shares:17.88M

Volume Ratio:0.68

T/O Rate:1.13%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1918

EPS(LYR):-2.1918

ROE:-41.80%

ROA:-22.90%

PB:4.21

PE(LYR):-9.35

Loading ...

Overview Company News Filings

Press Release: Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

Alto Neuroscience management to join Stifel Virtual CNS Forum fireside chat

BTIG Sticks to Their Buy Rating for Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience to Present at TD Cowen Annual Healthcare Conference

Analysts’ Top Healthcare Picks: Korro Bio (KRRO), Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience Is Maintained at Buy by BTIG

BRIEF-Alto Neuroscience Announces Completion Of Enrollment In Phase 2 Proof-Of-Concept Study Of Alto-101

Alto Neuroscience Completes Enrollment in Phase 2 Trial of ALTO-101 for Schizophrenia Cognitive Impairment

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of Alto-101 in Cognitive Impairment Associated With Schizophrenia

THOMSON REUTERS

Analysts Are Bullish on Top Healthcare Stocks: Grace Therapeutics (GRCE), Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience Identifies Neuroplasticity as Key Driver in Psychiatric Disease and Treatment

Sector Update: Health Care Stocks Mixed Premarket Wednesday

MT Newswires Live

Alto Neuroscience Secures New Patent for ALTO-207 Depression Treatment, Extending Protection Into Mid-2040s

Alto Neuroscience Unveils New EEG Biomarker Data Advancing Precision Psychiatry Treatments

Alto Neuroscience Showcases Precision Psychiatry Advances in New Corporate Presentation

Alto Neuroscience Is Maintained at Buy by Chardan Capital

Alto Neuroscience, Inc.'s (NYSE:ANRO) Intrinsic Value Is Potentially 33% Above Its Share Price

Simply Wall St.

Alto Neuroscience Currently Up Eight Consecutive Days, On Pace for Longest Winning Streak Since October 2024 -- Data Talk

Alto Neuroscience Grants New Employee Stock Option Under Inducement Plan

Alto Neuroscience Inc Files for Proposed Resale of up to 8.5 Mln Shares by Selling Stockholders - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ANRO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ANRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","market":"US","secType":"STK","nameCN":"Alto Neuroscience Inc","latestPrice":20.5,"timestamp":1774641600000,"preClose":20.82,"halted":0,"volume":201864,"hourTrading":{"tag":"盘后","latestPrice":20.5,"preClose":20.5,"latestTime":"18:16 EDT","volume":5724,"amount":117343.29,"timestamp":1774649765994,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.015369836695485124,"floatShares":17884024,"shares":31066335,"eps":-2.191806,"marketStatus":"Market Closed","change":-0.32,"latestTime":"03-27 16:00:00 EDT","open":20.7,"high":21.42,"low":19.85,"amount":4120911.9814,"amplitude":0.075408,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.191806,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1706850000000,"exchange":"NYSE","adjPreClose":20.82,"preHourTrading":{"tag":"盘前","latestPrice":22.06,"preClose":20.82,"latestTime":"09:01 EDT","volume":8,"amount":172.239992,"timestamp":1774616510453,"change":1.24,"changeRate":0.059558,"amplitude":0.050913},"postHourTrading":{"tag":"盘后","latestPrice":20.5,"preClose":20.5,"latestTime":"18:16 EDT","volume":5724,"amount":117343.29,"timestamp":1774649765994,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.679458,"impliedVol":1.2389,"impliedVolPercentile":0.5857},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","floatShares":17884024,"roa":"-22.90%","roe":"-41.80%","lyrEps":-2.191806,"volumeRatio":0.679458,"shares":31066335,"dividePrice":0,"high":21.42,"amplitude":0.075408,"preClose":20.82,"low":19.85,"week52Low":1.6,"pbRate":"4.21","week52High":25.17,"institutionHeld":0,"latestPrice":20.5,"eps":-2.191806,"divideRate":0,"volume":201864,"delay":0,"ttmEps":-2.191806,"open":20.7,"prevYearClose":17.8,"prevWeekClose":21.47,"prevMonthClose":19.69,"prevQuarterClose":17.8,"fiveDayClose":21.47,"twentyDayClose":19.69,"sixtyDayClose":17.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ANRO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-16","symbol":"ANRO","fiscalQuarterEnding":"2025/12","expectedEps":-0.56,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2025-11-12","symbol":"ANRO","fiscalQuarterEnding":"2025/09","expectedEps":-0.66,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2025-08-13","symbol":"ANRO","fiscalQuarterEnding":"2025/06","expectedEps":-0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.65}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ANRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ANRO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.4,"hold":0.1,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4,"analysts":10,"updateTime":1763438400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ANRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ANRO","date":"2026-03-27","current":-9.353018,"percent":0.115607,"low":-16.978804,"twenty":-8.978914,"median":-5.159821,"eighty":-1.327405,"high":-0.793245,"avg":-5.250645,"sd":3.911662,"marketCap":665105643},"quantilePoints":[{"date":"2024-02-09","current":-15.481605,"twenty":-16.048587,"median":-15.481605,"eighty":-13.872658,"marketCap":506867732},{"date":"2024-02-16","current":-12.96931,"twenty":-15.548491,"median":-13.234406,"eighty":-11.571235,"marketCap":424615224},{"date":"2024-02-23","current":-10.603839,"twenty":-15.481605,"median":-12.585941,"eighty":-11.026361,"marketCap":347169680},{"date":"2024-03-01","current":-12.56147,"twenty":-14.292343,"median":-12.488059,"eighty":-11.135662,"marketCap":411262544},{"date":"2024-03-08","current":-11.631595,"twenty":-13.230328,"median":-12.361629,"eighty":-11.293904,"marketCap":380818433},{"date":"2024-03-15","current":-12.153631,"twenty":-13.001937,"median":-12.137317,"eighty":-11.306955,"marketCap":397909864},{"date":"2024-03-22","current":-11.14409,"twenty":-12.949734,"median":-12.108768,"eighty":-11.306955,"marketCap":404586204},{"date":"2024-03-28","current":-12.415912,"twenty":-12.956259,"median":-12.145474,"eighty":-11.437463,"marketCap":450759680},{"date":"2024-04-05","current":-10.418119,"twenty":-12.920369,"median":-11.868143,"eighty":-11.162905,"marketCap":378229815},{"date":"2024-04-12","current":-10.440317,"twenty":-12.863272,"median":-11.793418,"eighty":-10.823597,"marketCap":379035702},{"date":"2024-04-19","current":-9.988964,"twenty":-12.713187,"median":-11.631595,"eighty":-10.532067,"marketCap":362649325},{"date":"2024-04-26","current":-10.455115,"twenty":-12.538631,"median":-11.566341,"eighty":-10.461035,"marketCap":379572960},{"date":"2024-05-03","current":-10.654895,"twenty":-12.497847,"median":-11.513206,"eighty":-10.478793,"marketCap":386825947},{"date":"2024-05-10","current":-10.802879,"twenty":-12.4592,"median":-11.360121,"eighty":-10.478793,"marketCap":392198529},{"date":"2024-05-17","current":-8.114957,"twenty":-12.377436,"median":-11.191128,"eighty":-10.431438,"marketCap":344382544},{"date":"2024-05-24","current":-7.443985,"twenty":-12.295701,"median":-11.079356,"eighty":-10.270134,"marketCap":315907856},{"date":"2024-05-31","current":-7.59948,"twenty":-12.254775,"median":-10.943138,"eighty":-9.999323,"marketCap":322506720},{"date":"2024-06-07","current":-7.453823,"twenty":-12.218885,"median":-10.773282,"eighty":-9.088414,"marketCap":316325341},{"date":"2024-06-14","current":-7.612146,"twenty":-12.153631,"median":-10.654895,"eighty":-8.114957,"marketCap":323044231},{"date":"2024-06-21","current":-6.997854,"twenty":-12.14058,"median":-10.580902,"eighty":-7.890353,"marketCap":296974938},{"date":"2024-06-28","current":-6.731872,"twenty":-12.125897,"median":-10.558705,"eighty":-7.854905,"marketCap":285687202},{"date":"2024-07-05","current":-7.35883,"twenty":-12.080219,"median":-10.514309,"eighty":-7.738804,"marketCap":312294007},{"date":"2024-07-12","current":-8.486086,"twenty":-11.912764,"median":-10.492111,"eighty":-7.738804,"marketCap":360132504},{"date":"2024-07-15","current":-8.840728,"twenty":-11.90384,"median":-10.492111,"eighty":-7.738804,"marketCap":375182817},{"date":"2024-08-02","current":-6.212575,"twenty":-11.894916,"median":-10.481012,"eighty":-7.674208,"marketCap":263649243},{"date":"2024-08-09","current":-5.762939,"twenty":-11.86488,"median":-10.440317,"eighty":-7.584281,"marketCap":244567596},{"date":"2024-08-16","current":-5.077305,"twenty":-11.842621,"median":-10.421819,"eighty":-7.439715,"marketCap":252875166},{"date":"2024-08-23","current":-5.770157,"twenty":-11.798049,"median":-10.270134,"eighty":-7.320833,"marketCap":287382652},{"date":"2024-08-30","current":-6.766131,"twenty":-11.747422,"median":-10.066655,"eighty":-7.023186,"marketCap":336987162},{"date":"2024-09-06","current":-6.885215,"twenty":-11.696849,"median":-9.985264,"eighty":-6.997854,"marketCap":342918136},{"date":"2024-09-13","current":-7.036776,"twenty":-11.629964,"median":-9.589405,"eighty":-7.005638,"marketCap":350466649},{"date":"2024-09-20","current":-7.269531,"twenty":-11.615282,"median":-8.800669,"eighty":-7.041657,"marketCap":362059007},{"date":"2024-09-27","current":-6.495486,"twenty":-11.576129,"median":-8.327763,"eighty":-6.997854,"marketCap":323507676},{"date":"2024-10-04","current":-5.51575,"twenty":-11.542663,"median":-8.073812,"eighty":-6.792939,"marketCap":274711934},{"date":"2024-10-11","current":-6.392641,"twenty":-11.505807,"median":-7.947789,"eighty":-6.506312,"marketCap":318385471},{"date":"2024-10-18","current":-7.724215,"twenty":-11.453451,"median":-7.863613,"eighty":-6.586066,"marketCap":384704544},{"date":"2024-10-25","current":-2.23553,"twenty":-11.361501,"median":-7.821648,"eighty":-6.506312,"marketCap":111340558},{"date":"2024-10-31","current":-2.181401,"twenty":-11.357822,"median":-7.776801,"eighty":-6.403467,"marketCap":108644661},{"date":"2024-11-08","current":-2.083968,"twenty":-11.223755,"median":-7.738804,"eighty":-6.212575,"marketCap":103792046},{"date":"2024-11-15","current":-2.159604,"twenty":-11.191128,"median":-7.724215,"eighty":-6.11117,"marketCap":124062772},{"date":"2024-11-22","current":-1.92017,"twenty":-11.14409,"median":-7.634377,"eighty":-5.98126,"marketCap":110307987},{"date":"2024-11-29","current":-2.070403,"twenty":-11.113816,"median":-7.615312,"eighty":-5.768005,"marketCap":118938440},{"date":"2024-12-06","current":-1.830969,"twenty":-11.06322,"median":-7.574148,"eighty":-5.648645,"marketCap":105183655},{"date":"2024-12-13","current":-1.798105,"twenty":-11.000259,"median":-7.504253,"eighty":-5.44863,"marketCap":103295743},{"date":"2024-12-20","current":-1.746462,"twenty":-10.916697,"median":-7.443985,"eighty":-5.07514,"marketCap":100329024},{"date":"2024-12-27","current":-2.075098,"twenty":-10.841355,"median":-7.436869,"eighty":-2.363274,"marketCap":119208142},{"date":"2025-01-03","current":-2.056319,"twenty":-10.79104,"median":-7.390494,"eighty":-2.255016,"marketCap":118129335},{"date":"2025-01-10","current":-2.070403,"twenty":-10.767363,"median":-7.35883,"eighty":-2.165554,"marketCap":118938440},{"date":"2025-01-17","current":-2.079793,"twenty":-10.725927,"median":-7.312287,"eighty":-2.141345,"marketCap":119477844},{"date":"2025-01-24","current":-2.272279,"twenty":-10.654895,"median":-7.277651,"eighty":-2.138097,"marketCap":130535613},{"date":"2025-01-31","current":-2.093877,"twenty":-10.603839,"median":-7.253293,"eighty":-2.122046,"marketCap":120286949},{"date":"2025-02-07","current":-1.854443,"twenty":-10.580902,"median":-7.17813,"eighty":-2.093877,"marketCap":106532163},{"date":"2025-02-14","current":-1.530502,"twenty":-10.558705,"median":-7.145034,"eighty":-2.075098,"marketCap":87922747},{"date":"2025-02-21","current":-1.464775,"twenty":-10.529107,"median":-7.061183,"eighty":-2.070403,"marketCap":84146924},{"date":"2025-02-28","current":-1.305152,"twenty":-10.515789,"median":-6.997854,"eighty":-2.041295,"marketCap":74977067},{"date":"2025-03-07","current":-1.854443,"twenty":-10.50839,"median":-6.933931,"eighty":-2.023455,"marketCap":106532163},{"date":"2025-03-14","current":-1.483554,"twenty":-10.495071,"median":-6.768,"eighty":-2.01289,"marketCap":85225730},{"date":"2025-03-21","current":-1.180996,"twenty":-10.492111,"median":-6.549615,"eighty":-1.993408,"marketCap":72549751},{"date":"2025-03-28","current":-1.062067,"twenty":-10.474353,"median":-6.422411,"eighty":-1.971812,"marketCap":65243830},{"date":"2025-04-04","current":-0.81528,"twenty":-10.458075,"median":-6.392641,"eighty":-1.92017,"marketCap":50083438},{"date":"2025-04-11","current":-0.903418,"twenty":-10.443277,"median":-6.253891,"eighty":-1.873222,"marketCap":55497864},{"date":"2025-04-17","current":-0.991556,"twenty":-10.440317,"median":-6.19297,"eighty":-1.833785,"marketCap":60912290},{"date":"2025-04-25","current":-1.004777,"twenty":-10.431438,"median":-6.11117,"eighty":-1.798105,"marketCap":61724454},{"date":"2025-05-02","current":-1.079695,"twenty":-10.421079,"median":-6.037568,"eighty":-1.742706,"marketCap":66326716},{"date":"2025-05-09","current":-0.965115,"twenty":-10.40924,"median":-5.975847,"eighty":-1.645994,"marketCap":59287962},{"date":"2025-05-16","current":-1.041186,"twenty":-10.323409,"median":-5.766106,"eighty":-1.583083,"marketCap":65785273},{"date":"2025-05-23","current":-1.255422,"twenty":-10.270134,"median":-5.686944,"eighty":-1.500455,"marketCap":79321337},{"date":"2025-05-30","current":-1.152589,"twenty":-10.199102,"median":-5.617282,"eighty":-1.480737,"marketCap":72824027},{"date":"2025-06-06","current":-1.019763,"twenty":-10.071835,"median":-5.469741,"eighty":-1.461958,"marketCap":64431667},{"date":"2025-06-13","current":-1.049756,"twenty":-10.02004,"median":-5.30697,"eighty":-1.408438,"marketCap":66326716},{"date":"2025-06-20","current":-0.972631,"twenty":-9.987484,"median":-5.077305,"eighty":-1.322054,"marketCap":61453732},{"date":"2025-06-27","current":-0.985485,"twenty":-9.980084,"median":-2.492642,"eighty":-1.263991,"marketCap":62265896},{"date":"2025-07-03","current":-1.006909,"twenty":-9.974165,"median":-2.341082,"eighty":-1.221144,"marketCap":63619503},{"date":"2025-07-11","current":-1.105457,"twenty":-9.589405,"median":-2.272279,"eighty":-1.163435,"marketCap":69846092},{"date":"2025-07-18","current":-1.233999,"twenty":-8.963166,"median":-2.213594,"eighty":-1.13545,"marketCap":77967731},{"date":"2025-07-25","current":-1.319693,"twenty":-8.840728,"median":-2.178383,"eighty":-1.148304,"marketCap":83382157},{"date":"2025-08-01","current":-1.315408,"twenty":-8.760609,"median":-2.161951,"eighty":-1.152589,"marketCap":83111436},{"date":"2025-08-08","current":-1.311123,"twenty":-8.486086,"median":-2.154336,"eighty":-1.163435,"marketCap":82840714},{"date":"2025-08-15","current":-1.302504,"twenty":-8.327763,"median":-2.124393,"eighty":-1.163435,"marketCap":84479082},{"date":"2025-08-22","current":-1.498714,"twenty":-8.182106,"median":-2.122046,"eighty":-1.165443,"marketCap":97205098},{"date":"2025-08-29","current":-1.590557,"twenty":-8.114957,"median":-2.098572,"eighty":-1.169728,"marketCap":103161956},{"date":"2025-09-05","current":-1.465317,"twenty":-8.049126,"median":-2.084227,"eighty":-1.178742,"marketCap":95038967},{"date":"2025-09-12","current":-1.640654,"twenty":-7.979964,"median":-2.075098,"eighty":-1.18912,"marketCap":106411151},{"date":"2025-09-19","current":-1.715798,"twenty":-7.951589,"median":-2.070403,"eighty":-1.198007,"marketCap":111284945},{"date":"2025-09-26","current":-1.586383,"twenty":-7.904286,"median":-2.056319,"eighty":-1.216859,"marketCap":102891190},{"date":"2025-10-03","current":-1.841039,"twenty":-7.881184,"median":-2.039887,"eighty":-1.228,"marketCap":119407933},{"date":"2025-10-10","current":-2.513164,"twenty":-7.867586,"median":-2.056319,"eighty":-1.233142,"marketCap":163001306},{"date":"2025-10-17","current":-2.454718,"twenty":-7.85227,"median":-2.070403,"eighty":-1.244282,"marketCap":159210578},{"date":"2025-10-24","current":-4.667305,"twenty":-7.827138,"median":-2.075098,"eighty":-1.253708,"marketCap":302716712},{"date":"2025-10-31","current":-5.978158,"twenty":-7.812987,"median":-2.084227,"eighty":-1.2897,"marketCap":387737327},{"date":"2025-11-07","current":-4.646431,"twenty":-7.783605,"median":-2.103267,"eighty":-1.301657,"marketCap":301362880},{"date":"2025-11-14","current":-4.738274,"twenty":-7.773873,"median":-2.122046,"eighty":-1.304622,"marketCap":307319739},{"date":"2025-11-21","current":-7.060871,"twenty":-7.758215,"median":-2.12674,"eighty":-1.306199,"marketCap":439588640},{"date":"2025-11-28","current":-6.91117,"twenty":-7.745076,"median":-2.154336,"eighty":-1.306688,"marketCap":430268739},{"date":"2025-12-05","current":-6.67664,"twenty":-7.738804,"median":-2.161951,"eighty":-1.306839,"marketCap":415667562},{"date":"2025-12-12","current":-7.325342,"twenty":-7.736546,"median":-2.178383,"eighty":-1.309247,"marketCap":456053797},{"date":"2025-12-19","current":-9.705579,"twenty":-7.761946,"median":-2.213594,"eighty":-1.311015,"marketCap":604240215},{"date":"2025-12-26","current":-9.920149,"twenty":-7.817318,"median":-2.253904,"eighty":-1.311123,"marketCap":617598739},{"date":"2026-01-02","current":-8.882226,"twenty":-7.875492,"median":-2.303191,"eighty":-1.311123,"marketCap":552980763},{"date":"2026-01-09","current":-7.929133,"twenty":-7.944058,"median":-2.354526,"eighty":-1.311807,"marketCap":493644063},{"date":"2026-01-16","current":-8.493005,"twenty":-8.098499,"median":-2.410079,"eighty":-1.314542,"marketCap":528749021},{"date":"2026-01-23","current":-8.572845,"twenty":-8.233524,"median":-2.467243,"eighty":-1.314542,"marketCap":533719635},{"date":"2026-01-30","current":-7.644703,"twenty":-8.248494,"median":-2.550736,"eighty":-1.315408,"marketCap":475936252},{"date":"2026-02-06","current":-7.040911,"twenty":-8.233524,"median":-2.675047,"eighty":-1.315408,"marketCap":438345986},{"date":"2026-02-13","current":-8.203584,"twenty":-8.278435,"median":-4.258185,"eighty":-1.315408,"marketCap":510730547},{"date":"2026-02-20","current":-9.730529,"twenty":-8.329873,"median":-4.59216,"eighty":-1.315408,"marketCap":605793532},{"date":"2026-02-27","current":-9.625739,"twenty":-8.433125,"median":-4.619295,"eighty":-1.315408,"marketCap":599269602},{"date":"2026-03-06","current":-10.26945,"twenty":-8.504981,"median":-4.688178,"eighty":-1.318836,"marketCap":639345174},{"date":"2026-03-13","current":-11.092803,"twenty":-8.596797,"median":-4.780021,"eighty":-1.319693,"marketCap":690604627},{"date":"2026-03-20","current":-10.997993,"twenty":-8.80207,"median":-5.077305,"eighty":-1.323121,"marketCap":684702023},{"date":"2026-03-27","current":-10.5175,"twenty":-8.978914,"median":-5.159821,"eighty":-1.327405,"marketCap":665105643}],"updateTime":1774734278354},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ANRO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619718459","title":"Press Release: Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2619718459","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619718459?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:03","pubTimestamp":1773655380,"startTime":"0","endTime":"0","summary":"-- Acquisition of ALTO-207 targets Treatment-Resistant Depression  with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 --. -- External PAX-D study published in The Lancet Psychiatry demonstrated a 0.87 effect size for the core mechanism of ALTO-207; this effect represents a significantly larger effect size than current standard-of-care treatments --. -- ALTO-101 granted FDA Fast Track Designation for CIAS; Topline Phase 2 Proof-of Concept data expected around the end of 1Q 2026 --. --  Acquisition and Accelerated Development of ALTO-207 for TRD: In June. patent coverage of ALTO-207 through at least the mid 204","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4588","BK4555","BK4099","TM","BK4007","ANRO","CIAS","BK4585","PIPE","03160"],"gpt_icon":0},{"id":"2619194743","title":"Alto Neuroscience management to join Stifel Virtual CNS Forum fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194743","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619194743?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:10","pubTimestamp":1773403824,"startTime":"0","endTime":"0","summary":"Alto Neuroscience will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET. The webcast will be available via the Events and Presentations page.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL2NzFjV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SF","ANRO","BK4127"],"gpt_icon":0},{"id":"2616883339","title":"BTIG Sticks to Their Buy Rating for Alto Neuroscience, Inc. (ANRO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616883339","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616883339?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:36","pubTimestamp":1772451404,"startTime":"0","endTime":"0","summary":"In a report released today, Thomas Shrader from BTIG maintained a Buy rating on Alto Neuroscience, Inc., with a price target of $28.00. According t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-their-buy-rating-for-alto-neuroscience-inc-anro-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-their-buy-rating-for-alto-neuroscience-inc-anro-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2613782726","title":"Alto Neuroscience to Present at TD Cowen Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613782726","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613782726?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:33","pubTimestamp":1771853590,"startTime":"0","endTime":"0","summary":"Alto Neuroscience to Present at TD Cowen Annual Healthcare Conference               Alto Neuroscience Inc. will participate in the TD Cowen 46th Annual Healthcare Conference in Boston, Massachusetts, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL9gnvXf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2612451569","title":"Analysts’ Top Healthcare Picks: Korro Bio (KRRO), Alto Neuroscience, Inc. (ANRO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612451569","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612451569?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:50","pubTimestamp":1771329051,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Korro Bio (KRRO – Research Report) and Alto Neurosci...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-korro-bio-krro-alto-neuroscience-inc-anro-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-korro-bio-krro-alto-neuroscience-inc-anro-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4007","BK4137","KRRO","LU0128526141.USD","XBI","BK4585","HCSG","XLV","LU0029874061.USD","ANRO","BK4581","LABU"],"gpt_icon":0},{"id":"2612566404","title":"Alto Neuroscience Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2612566404","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612566404?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:06","pubTimestamp":1771326360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 17, 2026 06:06 ET (11:06 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2611509271","title":"BRIEF-Alto Neuroscience Announces Completion Of Enrollment In Phase 2 Proof-Of-Concept Study Of Alto-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2611509271","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611509271?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:46","pubTimestamp":1770990412,"startTime":"0","endTime":"0","summary":"BRIEF-Alto Neuroscience Announces Completion Of Enrollment In Phase 2 Proof-Of-Concept Study Of Alto-101 Feb 13 (Reuters) - Alto Neuroscience Inc ANRO.N:ALTO NEUROSCIENCE ANNOUNCES COMPLETION OF ENROL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nTUA8T5KKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2611522011","title":"Alto Neuroscience Completes Enrollment in Phase 2 Trial of ALTO-101 for Schizophrenia Cognitive Impairment","url":"https://stock-news.laohu8.com/highlight/detail?id=2611522011","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611522011?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:04","pubTimestamp":1770987855,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire  on February 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL6jVKgX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2611220152","title":"Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of Alto-101 in Cognitive Impairment Associated With Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2611220152","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611220152?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:04","pubTimestamp":1770987840,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nTUA8T5KKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2611760929","title":"Analysts Are Bullish on Top Healthcare Stocks: Grace Therapeutics (GRCE), Alto Neuroscience, Inc. (ANRO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611760929","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611760929?lang=en_us&edition=fundamental","pubTime":"2026-02-13 01:30","pubTimestamp":1770917410,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Grace Therapeutics (GRCE – Research Report) and Alto...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-grace-therapeutics-grce-alto-neuroscience-inc-anro-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-grace-therapeutics-grce-alto-neuroscience-inc-anro-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4112","BK4007","LU0029874061.USD","BK4581","XBI","BK4588","BLSG","BK4137","BK4585","LABU","BLSX","ANRO","GRCE"],"gpt_icon":0},{"id":"2608564874","title":"Alto Neuroscience Identifies Neuroplasticity as Key Driver in Psychiatric Disease and Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2608564874","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608564874?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:42","pubTimestamp":1770126172,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc. announced the publication of a review article in the American Journal of Psychiatry, co-authored by members of its leadership team and board. The review consolidates clinical and translational evidence showing that disrupted neuroplasticity is a core biological driver across major psychiatric disorders such as depression, schizophrenia, PTSD, and addiction. The authors highlight the importance of developing translatable biomarkers for neuroplasticity changes in humans, a gap that Alto aims to address with its Precision Psychiatry Platform. The review supports Alto's strategy of pairing therapies with objective, circuit-level biomarkers and emphasizes the potential of targeting neuroplasticity as a measurable and druggable mechanism for improving psychiatric treatments. These results have already been published and are available online.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDLCF1Bf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2603439614","title":"Sector Update: Health Care Stocks Mixed Premarket Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2603439614","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603439614?lang=en_us&edition=fundamental","pubTime":"2026-01-14 22:24","pubTimestamp":1768400677,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF  slightly advancing and the iShares Biotechnology ETF  marginally lower.Astrazeneca  has acquired Modella AI, the companies said, without disclosing financial terms. Astrazeneca shares were up more than 1% pre-bell.Glaukos  stock was down more than 14% after the company reaffirmed its full-year 2026 revenue guidance of $600 million to $620 million.Alto Neuroscience  shares were up more than 1% after the company said it has been granted a US patent covering methods of treating depression with ALTO-207, which is a combination of pramipexole and ondansetron.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","LU2065731478.USD","AZN","LU2462157665.USD","IBB","LABU","XBI","BK4581","BK4588","BK4548","LU1829250122.USD","IE0009354923.USD","LU2456880835.USD","BK4007","BK4568","BK4082","LU2236285917.USD","XLV","GKOS","LU1878469433.USD","BK4585","LU2417539215.USD","ANRO"],"gpt_icon":0},{"id":"2603613717","title":"Alto Neuroscience Secures New Patent for ALTO-207 Depression Treatment, Extending Protection Into Mid-2040s","url":"https://stock-news.laohu8.com/highlight/detail?id=2603613717","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603613717?lang=en_us&edition=fundamental","pubTime":"2026-01-14 20:27","pubTimestamp":1768393633,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc. announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of pramipexole and ondansetron. The patent protects the use of ondansetron to mitigate pramipexole-related side effects, enabling patients to achieve higher doses needed for antidepressant benefits. The company expects its issued and pending claims to protect ALTO-207 into the mid-2040s, strengthening the intellectual property position of this investigational therapy for treatment-resistant depression.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire  on January 14, 2026, and is sole","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL2dMHVB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2603684884","title":"Alto Neuroscience Unveils New EEG Biomarker Data Advancing Precision Psychiatry Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2603684884","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603684884?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:02","pubTimestamp":1768309352,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire  on January 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL2jCdZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2602009590","title":"Alto Neuroscience Showcases Precision Psychiatry Advances in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2602009590","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602009590?lang=en_us&edition=fundamental","pubTime":"2026-01-12 17:24","pubTimestamp":1768209898,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc. has released a corporate presentation outlining progress in its precision medicine portfolio targeting central nervous system  disorders. The company highlighted advancements in multiple clinical-stage programs, including product candidates for depression, schizophrenia, bipolar depression, and Parkinson’s disease. Several trials are ongoing or have recently completed, with key data readouts anticipated over the next two years. Alto is leveraging a biomarker-based strategy to segment patient populations and drive improved clinical outcomes in CNS disorders. The presentation also notes a projected cash runway and provides updates on expected study milestones. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6GvWTV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2601884868","title":"Alto Neuroscience Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601884868","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601884868?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:26","pubTimestamp":1767619560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 08:26 ET (13:26 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2600038773","title":"Alto Neuroscience, Inc.'s (NYSE:ANRO) Intrinsic Value Is Potentially 33% Above Its Share Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2600038773","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600038773?lang=en_us&edition=fundamental","pubTime":"2026-01-01 19:23","pubTimestamp":1767266635,"startTime":"0","endTime":"0","summary":"Key Insights Using the 2 Stage Free Cash Flow to Equity, Alto Neuroscience fair value estimate is US$23.71 Alto...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-anro/alto-neuroscience/news/alto-neuroscience-incs-nyseanro-intrinsic-value-is-potential","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-anro/alto-neuroscience/news/alto-neuroscience-incs-nyseanro-intrinsic-value-is-potential","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK4100","ANRO","DCF","NYSE","TV","BK4007","FCF"],"gpt_icon":0},{"id":"2592043194","title":"Alto Neuroscience Currently Up Eight Consecutive Days, On Pace for Longest Winning Streak Since October 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2592043194","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592043194?lang=en_us&edition=fundamental","pubTime":"2025-12-20 03:54","pubTimestamp":1766174040,"startTime":"0","endTime":"0","summary":"Alto Neuroscience, Inc.  is currently at $19.48, up $0.03 or 0.15%. --Would be highest close since Feb. 5, 2024, when it closed at $21.80. --On pace for largest percent increase since Dec. 18, 2025, when it rose 6.93%. --Currently up eight consecutive days; up 47.02% over this period. --Longest winning streak since Oct. 16, 2024, when it rose for 10 straight trading days. --Up 360.52% year-to-date; on pace for best year on record . --Down 10.64% from its all-time closing high of $21.80 on Feb. 5, 2024. --Up 400.77% from 52 weeks ago , when it closed at $3.89. --Traded as high as $20.91; highest intraday level since Feb. 6, 2024, when it hit $21.64","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2588502125","title":"Alto Neuroscience Grants New Employee Stock Option Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2588502125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588502125?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:05","pubTimestamp":1764795925,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc. has granted a new employee an option to purchase 150,000 shares of its common stock at an exercise price of $12.80 per share, the closing price on the date of the grant. The stock option has a 10-year term and will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal monthly installments over the following 36 months, contingent on the employee's continued service with the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL8WgrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2586786289","title":"Alto Neuroscience Inc Files for Proposed Resale of up to 8.5 Mln Shares by Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2586786289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586786289?lang=en_us&edition=fundamental","pubTime":"2025-11-28 19:02","pubTimestamp":1764327752,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40EG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":85,"code":"91000000","status":"200"}]}}